دورية أكاديمية
Preventive Role of mTOR Inhibitor in Post-Kidney Transplant Urothelial Carcinoma.
| العنوان: | Preventive Role of mTOR Inhibitor in Post-Kidney Transplant Urothelial Carcinoma. |
|---|---|
| المؤلفون: | Chang YL; Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan., Lee HC; Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan., Luo HL; Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan., Chen YT; Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan., Chiang PH; Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan., Cheng YT; Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. Electronic address: ytsocheng@gmail.com. |
| المصدر: | Transplantation proceedings [Transplant Proc] 2019 Oct; Vol. 51 (8), pp. 2731-2734. Date of Electronic Publication: 2019 Aug 22. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Inc Country of Publication: United States NLM ID: 0243532 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2623 (Electronic) Linking ISSN: 00411345 NLM ISO Abbreviation: Transplant Proc Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York, N.Y. : Elsevier Science Inc. Original Publication: New York Stratton. |
| مواضيع طبية MeSH: | Kidney Transplantation*, Carcinoma, Transitional Cell/*epidemiology , Immunosuppressive Agents/*therapeutic use , Postoperative Complications/*epidemiology , Sirolimus/*therapeutic use, Adult ; Carcinoma, Transitional Cell/etiology ; Carcinoma, Transitional Cell/immunology ; Female ; Graft Rejection ; Graft Survival/drug effects ; Humans ; Immunocompromised Host ; Incidence ; Male ; Middle Aged ; Postoperative Complications/immunology ; Retrospective Studies ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Tacrolimus/therapeutic use ; Taiwan |
| مستخلص: | Background: There is little evidence about whether mammalian target of rapamycin (mTOR) inhibitor could prevent post-kidney transplant (KT) urothelial carcinoma (UC) or not. The aim of this study is to analyze the role of mTOR inhibitor add-on in tacrolimus-based kidney transplant recipients. Method: The data were obtained from the Kaohsiung Chang Gung Memorial Hospital using the Chang Gung Research Database and retrospectively reviewed from January 2000 to December 2015. Patients then were categorized into 2 groups: group FK (more than 2-year tacrolimus [FK] prescription) and group FK + mTOR inhibitor (more than 2-year tacrolimus plus at least 6-month continued sirolimus prescription). The primary end point is post-KT UC development. The secondary end point is mTOR inhibitor add-on effect on renal function deterioration episode. Results: There were 140 patients with tacrolimus-based immunosuppressant (group FK) and 82 patients with tacrolimus-based and add-on mTOR inhibitor regimen (group FK + mTOR inhibitor). The follow-up duration, sex distribution, and combined mycophenolate mofetil rate are similar in both groups. Younger age, lower tacrolimus trough level, lower UC incidence, and longer KT-to-UC interval were observed. Short- to intermediate-term results revealed noninferior graft outcome by creatinine level or creatinine deterioration. Conclusions: In our preliminary result, mTOR inhibitor add-on in patients with tacrolimus-based regimen revealed less post-KT UC occurrence. In addition, noninferior graft outcome was also observed. In Taiwan, a high UC prevalence area, mTOR inhibitor add-on strategy can be considered as a preventive strategy for UC after KT. (Copyright © 2019 Elsevier Inc. All rights reserved.) |
| المشرفين على المادة: | 0 (Immunosuppressive Agents) EC 2.7.1.1 (MTOR protein, human) EC 2.7.11.1 (TOR Serine-Threonine Kinases) W36ZG6FT64 (Sirolimus) WM0HAQ4WNM (Tacrolimus) |
| تواريخ الأحداث: | Date Created: 20190827 Date Completed: 20191220 Latest Revision: 20211204 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1016/j.transproceed.2019.03.059 |
| PMID: | 31447189 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder كن أول من يترك تعليقا!